Metagenomi Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Metagenomi Therapeutics Inc's ROI in the second quarter of 2026?
Metagenomi Therapeutics Inc recorded a cumulative net loss of $-93 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -50.72%.

Within the Healthcare sector 51 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3352 to 3550.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-32.81 %	-30.31 %	-28.51 %	15.11 %	96.45 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	146	174	198	218	239
Return On Investment (TTM)	-50.72 %	-41.39 %	-38.47 %	-35.4 %	-31.77 %
MGX's Overall Ranking	# 3550	# 3352	# 3195	# 3298	# 2859
Seq. Investment Change TTM	-11.2 %	-9.14 %	-8.89 %	-8.6 %	-7.9 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-93	-86	-88	-89	-87

MGX Company Profile >> Back to MGX Roi Comparisons >> See Annual MGX Return On Investment

Return On Investment MGX's Ranking
Within:	No.
Industry	# 3
Sector	# 52
Overall	# 3550

Return On Investment Statistics
High	Average	Low
-24.44 %	-35.48 %	-50.72 %
(Dec 31 2024)

Financial Statements
Metagenomi Therapeutics Inc's II. Quarter Investments	$ 146 Millions	MGX's Balance sheet
Metagenomi Therapeutics Inc's II. Quarter Income	$ -27 Millions	Quarterly MGX's Income Statement
MGX's Income by Division		See MGX's Income by Division

MGX Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024
Total Investments in Millions	198	287	0	0	0
Y / Y Investment Growth	-31.02 %	-	-	-	-
Net Income in Millions	-88	-78	0	0	0
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-44.34 %	-27.17 %	-	-	-

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
MGX's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for MGX's Competitors
Subscribers only: Roi for Metagenomi Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for MGX's Customers

Other Ratios
MGX's Roa	MGX's Inventory Turnover Ratio	MGX's Growth Rates	MGX's Dividend Statistics
	MGX's Profitability Ratios	MGX's Asset Turnover Ratio	MGX's Dividend Growth
MGX's Roe	MGX's Valuation Ratios	MGX's Financial Strength Ratios	MGX's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:43:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.